GlobeNewswire Clinical StudiesOriginal article
L’administration d’une seule perfusion de CARVYKTI®▼ (ciltacabtagène autoleucel) a permis d’obtenir une rémission sans traitement pendant cinq ans chez 50 pour cent des patients atteints d’un myélome multiple en rechute/réfractaire traité à un stade précoce du parcours thérapeutique
Phase 2positiveCARVYKTIPositive
AI Analysis
Summary
Johnson & Johnson announced 5-year follow-up data from CARTITUDE-2 Phase 2 trial showing 50% of early-line relapsed/refractory multiple myeloma patients treated with CARVYKTI maintained disease-free survival without maintenance therapy, supporting potential curative benefit of ciltacabtagène autoleucel.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Patients
20
Outcome Details
50% of patients (10/20) in early-line treatment achieved disease-free survival for at least 5 years without maintenance therapy
Importance:7/10
Sentiment:
0.85
CAR-T therapymultiple myelomalong-term follow-updurabilityearly-line treatment
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 28, 2026 12:19 PM